title: Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies.
abstract: We have previously shown that expression of heregulin (HRG) is closely correlated with breast cancer progression. We have subsequently isolated Cyr61, a ligand for the alpha(v)beta3 integrin that is differentially expressed in HRG-positive cells, and have shown that it is expressed in all of the invasive and metastatic breast cancer cell lines tested. Preliminary evaluation of Cyr61 expression in breast tumor biopsies revealed expression of Cyr61 in about 30% of invasive breast carcinomas. Significantly, we demonstrated that Cyr61 is a downstream effector of HRG action, because a Cyr61-neutralizing antibody abolished the ability of HRG-expressing cells to migrate in vitro. Furthermore, we have shown that HRG-expressing cells denote higher levels of alpha(v)beta3 expression, and we have established that Cyr61 action is mediated, at least in part, through its receptor alpha(v)beta3, because a functional blocking antibody of the alpha(v)beta3 blocked the Matrigel outgrowth of HRG-expressing cells. These results strongly suggest that Cyr61 is necessary for HRG-mediated chemomigration and that Cyr61 plays a functional role in breast cancer progression, possibly through its interactions with the alpha(v)beta3 receptor.
authors.affiliation: Ernest Lawrence Berkeley National Laboratory, University of California, Berkeley 94720, USA.
authors.forename: M S
authors.initials: MS
authors.lastname: Tsai
authors.forename: A E
authors.initials: AE
authors.lastname: Hornby
authors.forename: J
authors.initials: J
authors.lastname: Lakins
authors.forename: R
authors.initials: R
authors.lastname: Lupu
mesh_terms: D043925:Angiogenesis Inducing Agents / Q000096:biosynthesis / Q000378:metabolism / Q000502:physiology*; D000906:Antibodies / Q000494:pharmacology; D001706:Biopsy; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology*; D002465:Cell Movement / Q000502:physiology; D055515:Cysteine-Rich Protein 61; D018450:Disease Progression; D006133:Growth Substances / Q000096:biosynthesis / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D017874:Immediate-Early Proteins / Q000096:biosynthesis / Q000378:metabolism / Q000502:physiology*; D036341:Intercellular Signaling Peptides and Proteins; D009362:Neoplasm Metastasis; D020890:Neuregulin-1 / Q000096:biosynthesis; D011960:Receptors, Estrogen / Q000096:biosynthesis; D019030:Receptors, Vitronectin / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: D043925:Angiogenesis Inducing Agents; D000906:Antibodies; C501848:CCN1 protein, human; D055515:Cysteine-Rich Protein 61; D006133:Growth Substances; D017874:Immediate-Early Proteins; D036341:Intercellular Signaling Peptides and Proteins; D020890:Neuregulin-1; D011960:Receptors, Estrogen; D019030:Receptors, Vitronectin